321 related articles for article (PubMed ID: 30917858)
21. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
Skirnisdottir I; Seidal T
Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
[TBL] [Abstract][Full Text] [Related]
22. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
23. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours.
Athanassiadou P; Petrakakou E; Sakelariou V; Zerva C; Liossi A; Michalas S; Athanassiades P
Eur J Cancer Prev; 1998 Jun; 7(3):225-31. PubMed ID: 9696931
[TBL] [Abstract][Full Text] [Related]
24. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
25. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
26. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
27. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
28. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Kurman RJ; Shih IeM
Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
[TBL] [Abstract][Full Text] [Related]
31. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
32. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.
Köbel M; Reuss A; du Bois A; Kommoss S; Kommoss F; Gao D; Kalloger SE; Huntsman DG; Gilks CB
J Pathol; 2010 Oct; 222(2):191-8. PubMed ID: 20629008
[TBL] [Abstract][Full Text] [Related]
33. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
[TBL] [Abstract][Full Text] [Related]
34. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
[TBL] [Abstract][Full Text] [Related]
35. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
36. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
37. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
38. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
39. Precursors and pathogenesis of ovarian carcinoma.
Lim D; Oliva E
Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
[TBL] [Abstract][Full Text] [Related]
40. Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
Carter JH; Deddens JA; Mueller G; Lewis TG; Dooley MK; Robillard MC; Frydl M; Duvall L; Pemberton JO; Douglass LE
Br J Cancer; 2018 Aug; 119(4):462-470. PubMed ID: 30057405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
